March 31, 2025 03:45 PM EDT
R&D
Cell/Gene Tx

Tenaya to lay off about one-third of staff, re­veals heart gene ther­a­py da­ta

Lei Lei Wu

News Reporter

Heart gene ther­a­py mak­er Tenaya Ther­a­peu­tics is lay­ing off 30% to 40% of its staff by the end of the year, the com­pa­ny’s CEO Faraz …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Trump ad­min­is­tra­tion leaves obe­si­ty cov­er­age ex­pan­sion out of new Medicare rule

Marks was asked to pro­vide non-ex­is­tent vac­cine risk da­ta: WSJ

Kennedy team de­fends Marks fir­ing, while 20% of staff cuts may be 'mis­takes'

No­vavax’s held-up ap­proval pack­age may sig­nal warn­ing for Covid vac­cine mak­ers

Se­cre­tive Chi­nese start­up be­gins first-ever clin­i­cal tri­al of cir­cu­lar RNA ther­a­py

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times